Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies

Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies

Abstract Background Melanoma brain metastasis is associated with an extremely poor prognosis, with a median overall survival of 4–5 months. Since 2011, the overall survival of patients with stage IV melanoma has been significantly improved with the advent of new targeted therapies and checkpoint inh...

Full description

Bibliographic Details
Main Authors: Elham Vosoughi, Jee Min Lee, James R. Miller, Mehdi Nosrati, David R. Minor, Roy Abendroth, John W. Lee, Brian T. Andrews, Lewis Z. Leng, Max Wu, Stanley P. Leong, Mohammed Kashani-Sabet, Kevin B. Kim
Format: Article
Language:English
Published: BMC 2018-04-01
Series:BMC Cancer
Subjects:
Melanoma
Brain
Metastasis
Checkpoint inhibitors
BRAF
Online Access:http://link.springer.com/article/10.1186/s12885-018-4374-x

Internet

http://link.springer.com/article/10.1186/s12885-018-4374-x

Similar Items